DEFC14A: ETFS Capital Launches Proxy Fight Against WisdomTree, Urges Stockholders to Vote Against Re-election of Key Directors
Proxy Statement
ETFS Capital, a significant WisdomTree stockholder, is urging fellow stockholders to vote against the re-election of three key directors due to concerns over the company's strategic direction and value destruction.
Summary
- ETFS Capital Limited, owning 10% of WisdomTree's common stock, is soliciting proxies to vote against the re-election of Jonathan Steinberg, Win Neuger, and Anthony Bossone at the upcoming annual meeting.
- ETFS believes WisdomTree's management has pursued an ill-advised strategy of transforming the company into a DeFi business, leading to poor performance in the core ETF business and unsuccessful DeFi initiatives like WisdomTree Prime and Bitcoin ETFs.
- ETFS argues that WisdomTree trades at a significant discount to its intrinsic value as a well-run pure-play ETF business.
- They claim the core ETF business has been poorly managed, resulting in a lower operating margin (28.5%) compared to the industry standard (40-45%), and a loss of market share in the US ETF market.
- ETFS estimates that WisdomTree could reduce expenses by $58 million per annum, translating into an additional $613 million of stockholder value.
- ETFS also criticizes the company's DeFi initiatives, stating that WT Prime has failed to gain traction and the Bitcoin ETF has a minimal market share.
- ETFS proposes that the Board form a special committee to consider strategic alternatives, including a sale of the business and a repositioning of senior leadership.
- ETFS is urging stockholders to vote against the re-election of the three directors to send a strong message to the Board that change is needed.
- ETFS is not seeking to take over the company or nominate its own directors, but rather to compel the Board to restore value for all stockholders.
Sentiment
Score: 2
Explanation: The document expresses a highly negative sentiment towards WisdomTree's current management and strategic direction, highlighting significant concerns about value destruction and poor performance.
Negatives
- WisdomTree's DeFi strategy has led to poor management of the core ETF business.
- WisdomTree's operating margin is approximately 28.5%, while ETFS believes a well-run ETF business should have an operating margin of 40% to 45%.
- WisdomTree has lost significant ETF market share in the US, declining from 37% to 28% among its main competitors.
- WisdomTree's Bitcoin ETF has only garnered 0.2% market share.
- WT Prime has not been able to gain any traction, with run-rate revenues a mere $0.03 million per annum.
Risks
- The Board may not accept the resignations of the directors even if they fail to receive a majority vote.
- The Board may re-appoint the directors even if they are not re-elected.
- The Company's long-term growth strategy and value-creation initiatives could be undermined if the Board implements ETFS' proposals.
Future Outlook
ETFS believes that a strategic review is needed to unlock the value of WisdomTree's core ETF business and that change is needed to restore and unlock the true value of the Company.
Management Comments
- Mr. Tuckwell expressed his concern that the Company does not appear to be interested in having a two-way dialogue with ETFS.
- Mr. Tuckwell stated that ETFS had given the Board quite a lot of detailed information and suggestions regarding the Company and how to improve the Company in two presentations last year but had received no feedback to date.
- Mr. Tuckwell expressed his view that ETFS was politely listened to but completely ignored by the Board.
- Mr. Tuckwell explained his concerns that since mid-2018 the Company's assets under management (AUM) had almost doubled but the share price had remained stagnant because of poor management.
- The Board stated that, after reviewing ETFS proposals, it concluded not to implement any of them because the Board believed taking any of these actions would undermine the Company's long-term growth strategy and value-creation initiatives for the reasons set forth therein.
Industry Context
The document highlights the competitive landscape in the ETF market, particularly in the US and Europe, and compares WisdomTree's performance against its peers.
Comparison to Industry Standards
- ETFS asserts that a well-run ETF business should have an operating margin of 40% to 45%, based on the operating margin for Blackrock, Inc.'s ETF business.
- WisdomTree has lost significant ETF market share in the US compared to its main competitors (being ProShares, Van Eck and Global X).
- In Europe, where crypto ETFs have been listed for a number of years and WisdomTree was an early entrant, the Company is struggling in 4th place in issuer rankings.
- The app is a poor offering compared to what firms such as Schwab offer in our view and there is no logical reason for investors to sign up to it other than for those curious to see how bad it is.
Stakeholder Impact
- The outcome of the proxy solicitation could significantly impact shareholders, employees, and other stakeholders of WisdomTree.
Next Steps
- Stockholders are urged to vote AGAINST the re-election of Jonathan Steinberg, Win Neuger, and Anthony Bossone at the 2024 Annual Meeting.
- The Board will act on the recommendation of the Nominating and Governance Committee and will publicly disclose its decision within 90 days from the date of the certification of the election results.
Key Dates
| Date | Description |
|---|---|
| November 13, 2017 | Date of the Share Sale Agreement between WisdomTree and ETFS Capital. |
| April 11, 2018 | ETFS Capital acquired shares of Common Stock and Series A Preferred Stock. |
| June 16, 2023 | WisdomTree held its 2023 annual meeting of stockholders. |
| March 17, 2023 | The Board adopted the Poison Pill, which has subsequently been amended. |
| May 10, 2023 | The Company entered into and closed on a Sale, Purchase and Assignment Deed (the SPA Agreement) relating to the Contractual Gold Payments. |
| February 13, 2024 | Mr. Tuckwell met with certain members of the Board, Win Neuger and Tonia Pankopf. |
| February 20, 2024 | ETFS sent a private letter to Mr. Neuger and Ms. Pankopf following up on their February 13, 2024 meeting. |
| February 27, 2024 | The Company issued a public letter to ETFS in response to ETFS private letter to the Board. |
| March 18, 2024 | The Company announced it was extending the expiration of its Poison Pill to March 17, 2025. |
| March 21, 2024 | ETFS issued a public letter to stockholders in response to the Company's unconventional public response to Mr. Tuckwell's private communications to the Board. |
| April 12, 2024 | The Company filed a preliminary proxy statement with the SEC in connection with the 2024 Annual Meeting. |
| April 17, 2024 | ETFS filed its preliminary proxy statement with the SEC in connection with the 2024 Annual Meeting. |
| April 19, 2024 | The Company filed a new preliminary proxy statement with the SEC in connection with the 2024 Annual Meeting. The Company has set the close of business on April 19, 2024 as the record date for determining stockholders entitled to notice of and to vote at the 2024 Annual Meeting (the Record Date). |
| April 26, 2024 | The Company filed a revised preliminary proxy statement with the SEC in connection with the 2024 Annual Meeting. |
| April 29, 2024 | The Company filed its definitive proxy statement with the SEC in connection with the 2024 Annual Meeting. |
| April 30, 2024 | ETFS filed a revised preliminary proxy statement with the SEC in connection with the 2024 Annual Meeting. |
| May 3, 2024 | ETFS filed this definitive proxy statement with the SEC in connection with the 2024 Annual Meeting. This Proxy Statement and the enclosed GOLD proxy card are first being furnished to stockholders on or about May 3, 2024. |
| June 12, 2024 | Date of the 2024 Annual Meeting of Stockholders. |
| December 30, 2024 | Deadline for stockholders to submit proposals for inclusion in the Company's proxy materials for the 2025 Annual Meeting. |
| December 30, 2024 | Earliest date for stockholders to deliver director nominations under the proxy access bylaw provision. |
| January 29, 2025 | Latest date for stockholders to deliver director nominations under the proxy access bylaw provision. |
| February 12, 2025 | Earliest date for stockholders to deliver notice of proposals of business or nominations for directors for the 2025 Annual Meeting. |
| March 14, 2025 | Latest date for stockholders to deliver notice of proposals of business or nominations for directors for the 2025 Annual Meeting. |
| March 17, 2025 | Expiration date of the Poison Pill, unless stockholders ratify the Board's approval of the extension. |
Keywords
WisdomTree, ETFS Capital, proxy fight, ETF, DeFi, Jonathan Steinberg, Win Neuger, Anthony Bossone, strategic review, stockholder value, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.